- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04190862
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Study Overview
Detailed Description
The purpose of this study is to test the safety of E-CEL UVEC® cells and see what effects (good and bad) it has on your anal fistula. It is hoped, that the E-CEL UVEC® cells may help to improve healing of your fistula after surgery.
E-CEL UVEC® cells are genetically engineered human endothelial cells that are taken from the umbilical cords of newborn babies. The endothelial cells are cells that line the inside of blood vessels including the umbilical cord. Human umbilical endothelial cells are collected from the umbilical cord of a healthy newborn baby. The cells are obtained under strict United States (U.S.) Food and Drug Administration (FDA) regulations. The endothelial cells are engineered in the laboratory, meaning an extra gene is added. A gene is taken from a virus (just a single gene, not the entire virus) and inserted into the endothelial cells.This causes the endothelial cells to be more stable and improves their growth capabilities. In animal studies, the endothelial cells were cleared from the body within a month. No negative side effects related to the endothelial cells were seen in animal studies. A higher than normal healing response was seen in animal studies.
This research study is being done because, in animal studies, E-CEL UVEC® cells have been shown to speed up healing in various tissues and organs. This study will test if it is safe to use E-CEL UVEC® cells and if they help to improve healing of your fistula after surgery.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Julianna Brouwer, MPH
- Phone Number: 6469622394
- Email: jub2024@med.cornell.edu
Study Contact Backup
- Name: Rohit Rasane
- Phone Number: 646-962-2789
- Email: rkr4004@med.cornell.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medical College - NewYork-Presbyterian Hospital
-
Contact:
- Julianna Brouwer
- Phone Number: 646-962-2394
- Email: jub2024@med.cornell.edu
-
Sub-Investigator:
- Heather Yeo, MD
-
Sub-Investigator:
- Kelly Garrett, MD
-
Sub-Investigator:
- Lea Lowenfeld, MD
-
Sub-Investigator:
- Alessio Pigazzi, MD, PhD
-
Sub-Investigator:
- Mehraneh Jafari, MD
-
Principal Investigator:
- Jeffrey Milsom, MD
-
Contact:
- Rohit Rasane
- Phone Number: 646-962-2789
- Email: rkr4004@med.cornell.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject ages 18 or older
- Subject willing and able to provide informed consent
- Subject is medically eligible and have agreed to undergo a fistulotomy
- Subject with simple perianal fistula with 2 or fewer fistula tracts
- Maximum tract length of 3 inches
- Subject without history of Crohn's disease/ Ulcerative Colitis
- For female subjects of childbearing potential:
- A negative serum or urine pregnancy test at screening is required prior to enrollment
- Subject must be willing to use a highly effective method of contraception from the start of the screening period throughout the study period
- For males who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception:
- Subject must be willing to use a recommended method of contraception and refrain from sperm donation from the start of the conditioning therapy for at least 1 year after completion and discussion with a treating physician
Exclusion Criteria:
- Concomitant rectovaginal fistulas
- Subjects with an abscess
- Presence of active infections findings (e.g.; redness, swelling, tenderness or fever)
- Presence of rectal and/or anal stenosis
- The presence of setons unless removed prior to the treatment
- Subjects with ongoing steroid treatment or treated with steroids in the last 4 weeks
- Subjects with HbA1c ≥ 7.0
- Renal impairment defined by creatinine clearance below 90 mL/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)
- Hepatic impairment defined by both of the following laboratory ranges:
- Total bilirubin ≥ 1.5 x ULN unless benign congenital hyperbilirubinemia
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2.5 x ULN
- Known history of abuse of alcohol or other addictive substances in the 6 months prior to enrollment
- Active malignant tumor within 5 years
- Current recent history of abnormal, severe, progressive, uncontrolled hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases
- Congenital or acquired immunodeficiencies including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
- Major surgery or severe trauma within the previous 6 months
- Females who are who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment
- Subjects who have known hypersensitivity or documented allergy to DMSO
- Subjects who do not wish to or cannot comply with study procedures
- Subjects currently receiving, or having received any investigational drug within 3 months prior to E-CEL UVEC cell therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cell Therapy Treatment
Patients who present with simple anal fistula and elect to undergo fistulotomy for treatment will be eligible to have E-CEL UVEC injected into the fistula at the time of fistulotomy to aid in healing.
|
Injection of E-CEL UVEC
|
Experimental: Cell Therapy Treatment Part B
Adult subjects with simple perianal fistula who meet all eligibility criteria to participate in Part B of the study will be treated in the outpatient setting with curettage and E-CEL UVEC cells without fistulotomy.
E-CEL UVEC cells will be injected along the two sides (180 degrees apart from each other) of the whole length of the curetted anal fistula tract.
|
Injection of E-CEL UVEC
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of dose escalation, as measured by incidence rate of treatment emergent adverse events following the administration of E-CEL UVEC
Time Frame: 2 weeks
|
The short term safety of escalating dose of E-CEL UVEC cells in subjects with anal fistulas will be assessed by monitoring and recording all adverse events for 2 weeks following the administration of E-CEL UVEC.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-Term Safety of E-CEL UVEC, as measured by the number of adverse events at 6 weeks following the administration of E-CEL UVEC
Time Frame: 6 weeks
|
The long term safety of E-CEL UVEC cells in subjects with anal fistulas will be by assessed by monitoring and recording adverse events for 24 weeks following the administration of E-CEL UVEC.
|
6 weeks
|
Long-Term Safety of E-CEL UVEC, as measured by the number of adverse events for 24 weeks following the administration of E-CEL UVEC
Time Frame: 24 weeks
|
The long term safety of E-CEL UVEC cells in subjects with anal fistulas will be by assessed by monitoring and recording adverse events for 24 weeks following the administration of E-CEL UVEC.
|
24 weeks
|
Efficacy of E-CEL UVEC, as measured the rate of subjects presenting with relapse in treated fistula
Time Frame: 6, 24 weeks after surgery
|
Efficacy of E-CEL UVEC, as measured the rate of subjects presenting with relapse in treated fistula at week 6 and 24
|
6, 24 weeks after surgery
|
Efficacy of E-CEL UVEC, as measured by time to complete healing of each side
Time Frame: 24 weeks after surgery
|
Efficacy of E-CEL UVEC, as measured by time to complete healing of each side of injection site
|
24 weeks after surgery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jeffrey W Milsom, MD, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-04020122
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal Fistula
-
Zagazig UniversityCompletedTranssphincteric Anal FistulaEgypt
-
F Care Systems NVNot yet recruiting
-
Chinese University of Hong KongTerminated
-
Societa Italiana di Chirurgia ColoRettaleTerminated
-
Mansoura UniversityUnknownVideo Assisted Anal Fistula TreatmentEgypt
-
Groupe Hospitalier Paris Saint JosephCompletedComplex Anal FistulaFrance
-
Assiut UniversityActive, not recruiting
-
University Hospital, Clermont-FerrandUnknown
-
Dr Benjamin NEBBOTSuspended
-
University of Southern DenmarkOdense University HospitalCompleted
Clinical Trials on E-CEL UVEC
-
Hospital for Special Surgery, New YorkAngiocrine BioscienceActive, not recruitingRotator Cuff Tears | Muscle Atrophy or Weakness | Safety Issues | Tendon Rupture - ShoulderUnited States
-
Angiocrine BioscienceCalifornia Institute for Regenerative Medicine (CIRM)TerminatedHodgkin Lymphoma | Non Hodgkin LymphomaUnited States
-
TruDiagnosticSRWRecruiting
-
Shanghai Ming Ju Biotechnology Co., Ltd.RecruitingSystemic Lupus ErythematosusChina
-
Kamau TherapeuticsRecruitingSickle Cell DiseaseUnited States
-
University Medical Center GroningenStichting Hemato-Oncologie voor Volwassenen NederlandRecruitingNHL | DLBCL - Diffuse Large B Cell LymphomaNetherlands
-
Vertex Pharmaceuticals IncorporatedCRISPR TherapeuticsEnrolling by invitationHematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-ThalassemiaUnited States, Canada, Italy, United Kingdom, Germany
-
CelgeneCompletedLymphoma, Non-HodgkinItaly, Switzerland, Austria, Belgium, France, Germany, Japan, Netherlands, Spain, United Kingdom, Finland
-
bluebird bioCompletedCerebral Adrenoleukodystrophy (CALD)United States, Germany, Argentina, Australia, France, United Kingdom